We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline (GSK) has entered a definitive agreement to sell its entire equity stake in royalty management company Innoviva at $12.25 for each share, taking the deal proceeds to a total of nearly $392m.
GSK noted that while bronchodilation is recognised as the foundation of COPD therapy, “many patients may continue to struggle with symptoms and exacerbations over time”.
US-based small molecule medicines provider Innoviva (formerly Advanced Medicine) has announced a private placement of convertible senior notes due 2025 to raise $175m.
US-based small molecule medicines provider Innoviva (formerly Advanced Medicine) has announced a private placement of convertible senior notes due 2025 to raise $175m.